{"pub_date": "2016-07-29T17:25:32+0000", "subsection_name": null, "lead_paragraph": "It wasn\u2019t just soaring drug prices that helped Valeant Pharmaceuticals\u2019 cash flow. A credit for inventories at those higher prices also plumped the figures.", "print_page": "1", "document_type": "article", "byline": {"contributor": "", "person": [{"rank": 1, "organization": "", "lastname": "MORGENSON", "firstname": "Gretchen", "role": "reported"}], "original": "By GRETCHEN MORGENSON"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/07/31/business/31gret1/31gret1-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/07/31/business/31gret1/31gret1-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 400, "url": "images/2016/07/31/business/31gret1/31gret1-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/07/31/business/31gret1/31gret1-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/07/31/business/31gret1/31gret1-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/07/31/business/31gret1/31gret1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"content_kicker": "Fair Game", "print_headline": "Two Bumps From One Price Jump", "main": "How Valeant Cashed In Twice on Higher Drug Prices", "kicker": "Fair Game"}, "source": "The New York Times", "blog": [], "word_count": "1167", "web_url": "http://www.nytimes.com/2016/07/31/business/how-valeant-cashed-in-twice-on-higher-drug-prices.html", "slideshow_credits": null, "news_desk": "SundayBusiness", "type_of_material": "News", "snippet": "It wasn\u2019t just soaring drug prices that helped Valeant Pharmaceuticals\u2019 cash flow. A credit for inventories at those higher prices also plumped the figures....", "_id": "579b918e38f0d83c0fcf7790", "abstract": "Gretchen Morgenson Fair Game column explains second way Valeant Pharmaceuticals International benefited from its highly questionable drug pricing policies; notes firm's excessive drug price increases also inflated its operating cash flow through so-called price appreciation credits, practice in which company receives credit from wholesalers reflecting impact of that price increase on those wholesalers' current inventory. ", "keywords": [{"rank": "1", "name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N"}, {"rank": "3", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N"}, {"rank": "4", "name": "persons", "value": "Pearson, John Michael (1959- )", "is_major": "N"}]}